20 articles
A pilot study shows cervical spinal cord stimulation restored hand and arm function in stroke patients, with a 32% strength gain when switched on.
The Modius Spero uses electrical vestibular stimulation via ear electrodes in 30-min daily sessions, with two-thirds of trial users improving.
VERVE-102 permanently silences the PCSK9 gene in a single dose, slashing LDL cholesterol up to 62% with encouraging early safety data.
Vasa Therapeutics advances VS-214, a peptide targeting poor limb circulation, toward first human trials in 2026 — addressing a massively underserved condition.
A biotech firm's preclinical data shows an IV-delivered gene therapy can reach the brain and silence tau — no invasive procedure required.
Engineered heart muscle patches from stem cells thickened weakened heart walls and improved pumping ability in a small human trial.
Cognito's Spectris device increased HDL-like lipid transport proteins in cerebrospinal fluid of mild cognitive impairment patients.
Engineered cardiac patches called BioVAT improved heart function and quality of life in early-stage heart failure patients.
Voyager's one-time IV gene therapy slashed tau protein by 75% in primates. Human trials begin late 2026.
Aspen Neuroscience's stem cell therapy restored dopamine neurons in Parkinson's patients, adding ~2 hours of controlled movement daily.
Voyager's VY1706 slashed tau protein up to 64% in primate brains after one IV dose, with no adverse effects found.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
Leal Therapeutics launches first-in-human trial of LTX-002, an antisense drug targeting toxic lipid buildup in ALS motor neurons.
Junevity's GalNAc siRNA candidate restores healthier gene expression in diabetic mice with no safety signals, targeting cardiometabolism and neurodegeneration.
Sironax's SARM1 inhibitor SIR2501 wins FDA Fast Track status for chemotherapy-induced nerve damage, with trials also targeting ALS.
The AVANT GUARD trial shows PFA nearly doubles success rates vs drugs for persistent atrial fibrillation, published in NEJM.
Cambridge researchers found a gene network that shuts off nerve repair — and an existing hormone drug that reactivates it.
Duke researchers restored healthy mitochondria to damaged nerve cells, cutting pain-related behaviors by 50% in mice with nerve pain.
A novel transcatheter mitral valve replacement system shows sustained valve performance and low complications at 1 year in early trial data.
A small prospective trial shows adding immunotherapy to chemo before surgery dramatically improves outcomes in complex NSCLC patients.
